BackBetter Therapeutics- Tradeable Rights - March 2021 Overview

Better Therapeutics- Tradeable Rights - March 2021 Selling, General & Admin

Better Therapeutics- Tradeable Rights - March 2021 selling, general & admin — quarterly history, peer benchmarks, and growth trends.

Get informed when a big investor buys or sells

+ Follow

Quarterly SG&A Expenses

$3.51M
36.44% YoY

As of Sep 30, 2023

Annual SG&A Expenses (TTM)

$19.10M
14.34% YoY

Trailing 12 months ending Sep 30, 2023

Average SG&A Expenses (Comparison Companies)

Selling, General & Admin History

Selling, General & Admin Comparison

Annual Selling, General & Admin Growth Rate (%)

Annual Selling, General & Admin Growth (Absolute)

Better Therapeutics- Tradeable Rights - March 2021 (MCADR) FAQ

Stockcircle tracks selling, general & admin for Better Therapeutics- Tradeable Rights - March 2021 (MCADR), including historical charts and peer comparisons when data is available. Check back as new filings are published, or open the stock overview for a broader fundamental snapshot.

This Selling, General & Admin page is built for Better Therapeutics- Tradeable Rights - March 2021's historical SG&A expenses trend and peer context. When enough reporting periods are on file, the charts below visualize how the metric has moved over time.

Use SG&A expenses as one input alongside growth, profitability, valuation, and ownership activity. Stockcircle links related metric pages and the main MCADR overview so you can move from this figure to the surrounding analysis quickly.